Effects of Climate Change in Movement Disorders

Erscheinungsjahr 2026
ISBN: 978-0-443-41616-3
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Effects of Climate Change in Movement Disorders, Volume 10 in the International Review of Movement Disorders series, highlights new advances in the field, with this updated volume presenting interesting chapters on a variety of timely topics, including Climate Change and the Global Burden of Parkinson’s Disease and Movement Disorders, Air Pollution and Neurotoxicity: The Role of Environmental Pollutants in Movement Disorders, Extreme Heat, Sleep Disruption, and the Glymphatic System: Implications for Parkinson’s Disease, Climate-Driven Changes in Vector-Borne Diseases and Neuroinfections: Risks for Movement Disorders, The Impact of Climate Change on Food Security and Nutritional Deficiencies in Movement Disorders, and much more.

Other sections cover Invisible Invaders: The Emerging Threat of Microplastics to Brain Health and Movement Disorders, Socioeconomic and Healthcare Disparities in Climate-Related Vulnerability for Parkinson's Disease and Movement Disorders, The Role of Heat Stress, Oxidative Damage, and Neuroinflammation in Parkinson’s disease Pathophysiology, Climate-Linked Disruptions in Medication Availability and Treatment Strategies in movement disorders, and more.

Autoren/Hrsg.

Weitere Mitwirkende

Jenner, Peter

King, Tan Eng

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Technische Wissenschaften Elektronik | Nachrichtentechnik Elektronik
• Naturwissenschaften Physik Thermodynamik Festkörperphysik, Kondensierte Materie
• Technische Wissenschaften Maschinenbau | Werkstoffkunde Technische Mechanik | Werkstoffkunde
• Naturwissenschaften Physik Physik Allgemein

Inhaltsverzeichnis

1. Climate Change and the Global Burden of Parkinson’s Disease and Movement Disorders
2. Air Pollution and Neurotoxicity: The Role of Environmental Pollutants in Movement Disorders
3. Extreme Heat, Sleep Disruption, and the Glymphatic System: Implications for Parkinson’s Disease
4. Climate-Driven Changes in Vector-Borne Diseases and Neuroinfections: Risks for Movement Disorders
5. The Impact of Climate Change on Food Security and Nutritional Deficiencies in Movement Disorders
6. Invisible Invaders: The Emerging Threat of Microplastics to Brain Health and Movement Disorders
7. Socioeconomic and Healthcare Disparities in Climate-Related Vulnerability for Parkinson's Disease and Movement Disorders
8. The Role of Heat Stress, Oxidative Damage, and Neuroinflammation in Parkinson’s disease Pathophysiology
9. Climate-Linked Disruptions in Medication Availability and Treatment Strategies in movement disorders
10. Mental Health, Climate Anxiety, and Progression of Parkinson's Disease and Movement Disorders
11. Policy, Advocacy, and Climate-Resilient Care for Parkinson's Disease and Movement Disorders

Über Autor(innen)

Jenner, Peter
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.